The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test

This study has been completed.
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT00638430
First received: March 12, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
  Purpose

The purpose of this study is to examine the effect of the myopic optical defocus on the Humphrey Matrix 30-2 test.


Condition
Myopia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • mean defect [ Time Frame: 15 minutes ] [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: March 2007
Study Completion Date: March 2008
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
low myopic group
2
moderate myopic group

Detailed Description:

The Humphery Matrix (Zeiss, Dublin, California, USA; in cooperation with Welch Allyn, Skaneateles, New York, USA), which is a recently developed version of FDT perimetry, showed more improved technology to detect early glaucomatous damage. The user's guide for the Humphrey Matrix (Humphrey® matrix visual field instrument user's guide. Zeiss, Dublin, California, USA; in cooperation with Welch Allyn, Skaneateles, New York, USA; 2003) suggests that myopic refractive errors more than -3.0 D need to be corrected before the 30-2 test. However, the proper correction of the optical defocus is not always easy because of a lack of trial frame.

The purpose of the present study is twofold. At first, the influence of the low-grade myopia on the Humphery Matrix 30-2 test will be evaluated and compared to the effect of moderate-grade myopia. Secondly, the influence of myopic optical defocus and the glaucomatous visual field damage on the pattern deviation plot change according to the severity of glaucomatous visual field damage will be estimated.

  Eligibility

Ages Eligible for Study:   27 Years to 61 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

tertiary care clinic

Criteria

Inclusion Criteria:

  • intra-ocular pressure 23 or higher
  • suspicious glaucomatous optic disc change
  • suspicious defect of retinal nerve fiber layer
  • or eyes with various degrees of glaucoma

Exclusion Criteria:

  • a high myopic eye (SE more than -6.0 D)
  • moderate to severe cataract
  • evidence of diabetic or hypertensive retinopathy
  • macular disease
  • intra-ocular inflammation
  • history of intraocular surgery and any other ocular lesion that could have an influence on the perimetry result
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00638430

Locations
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 130-710
Sponsors and Collaborators
Samsung Medical Center
Investigators
Study Chair: Changwon Kee, M.D. Department of Ophthalmology, Samsung Medical Center,
  More Information

Publications:
Responsible Party: Changwon Kee, Department of Ophthalmology, Samsung Medical Center,
ClinicalTrials.gov Identifier: NCT00638430     History of Changes
Other Study ID Numbers: Humphrey30-2
Study First Received: March 12, 2008
Last Updated: March 12, 2008
Health Authority: South Korea: Institutional Review Board

Keywords provided by Samsung Medical Center:
myopia
Humphery Matrix 30-2 test

Additional relevant MeSH terms:
Myopia
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on August 21, 2014